Bladder Cancer

Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center

VIDEOS

Enfortumab Vedotin Plus Pembrolizumab Induces High Response Rates in Cisplatin-Ineligible Patients With Urothelial Cancer

09/20/2022

Allison Casey

Jonathan Rosenberg, MD, reviews findings from a cohort study evaluating enfortumab vedotin monotherapy or enfortumab vedotin in combination with pembrolizumab for cisplatin-ineligible patients with urothelial cancer.

Jonathan Rosenberg, MD, reviews...

09/20/2022

Oncology

News

Improvements in Bladder Cancer Mortality in the US Are Not Equitably Distributed

02/24/2022

An overall decrease in the incidence of bladder cancer mortality in the United States was not shared among micropolitan (rural) populations, revealing Black and rural populations experienced a significant worsening of mortality, presented at...

An overall decrease in the...

02/24/2022

Oncology

Videos

Avelumab-Based Neoadjuvant Chemotherapy for Patients With Non–Metastatic, Muscle-Invasive Bladder Cancer: AURA Trial

11/11/2021

Nieves Martínez Chanzá, MD, PhD, discusses the AURA trial evaluating avelumab as the basis of neoadjuvant chemotherapy in platinum-eligible and ineligible patients with non-metastatic muscle-invasive bladder cancer.

Nieves Martínez Chanzá, MD, PhD,...

11/11/2021

Oncology

Videos

Dr Powles Reviews NORSE Study Results in FGFR3, FGFR2 Genetically Altered mUC

10/27/2021

Thomas Powles, MRCP, MD, discusses evaluating erdafitinib in combination with cetrelimab in patients with locally advanced or mUC with FGFR3 or FGFR2 genetic alterations ineligible for cisplatin.

Thomas Powles, MRCP, MD,...

10/27/2021

Oncology

Videos

Dr Grivas Discusses Updates from the JAVELIN Bladder 100 Trial

06/29/2021

Petros Grivas, MD, PhD, highlights updates from the phase III JAVELIN Bladder 100 trial for advanced urothelial carcinoma.

Petros Grivas, MD, PhD,...

06/29/2021

Oncology

Videos

Dr Grivas Discusses Trial Results of Nivolumab or Lirilumab for MIBC

06/27/2021

Petros Grivas, MD, PhD, discusses phase Ib trial results of neoadjuvant nivolumab or lirilumab for cisplatin-ineligible patients with MIBC.

Petros Grivas, MD, PhD,...

06/27/2021

Oncology

Podcasts

No DFS Benefit With Adjuvant Atezolizumab for High-Risk Urothelial Carcinoma

02/12/2021

Petros Grivas, MD, PhD, talks about the importance of the IMvigor010 clinical trial, which assessed the use of adjuvant atezolizumab in patients with muscle-invasive urothelial cancer.

Petros Grivas, MD, PhD, talks...

02/12/2021

Oncology

Videos

Maintenance Avelumab With Best Supportive Care Improves OS in Urothelial Cancer

05/31/2020

Petros Grivas, MD, PhD, discusses interim findings from the phase 3 JAVELIN Bladder 100 clinical trial presented at the virtual 2020 ASCO Annual Meeting.

Petros Grivas, MD, PhD,...

05/31/2020

Oncology

News

Radical Cystectomy, PLND Safe After Neoadjuvant Pembrolizumab for Bladder Cancer

01/23/2020

Study findings support the safety of radical cystectomy and PLND in patients with nonmetastatic bladder cancer who received neoadjuvant pembrolizumab.

Study findings support the...

01/23/2020

Oncology